BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivozanib: Additional Phase II data

Additional data from a placebo-controlled Phase II trial in 272 patients naïve to VEGF therapy showed that once-daily oral tivozanib led to a median PFS of 11.8 months. Median PFS for patients with clear cell RCC who had undergone a prior nephrectomy was 14.8 months. Additionally, PFS was significantly higher in patients with...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >